Difference between revisions of "Iptacopan (Fabhalta)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
<br>Route: oral | <br>Route: oral | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/drug/soliris-eculizumab-342875 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)] |
| − | ==Diseases for which it is | + | ==Toxicity management== |
| + | *'''[https://www.fabhalta-hcp.com/pnh/about-pnh Link to REMS program]''' | ||
| + | |||
| + | ==Diseases for which it is established== | ||
*[[Paroxysmal nocturnal hemoglobinuria]] | *[[Paroxysmal nocturnal hemoglobinuria]] | ||
| − | |||
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 12 | + | *2023-12-05: Approved for the treatment of adults with [[Paroxysmal nocturnal hemoglobinuria|paroxysmal nocturnal hemoglobinuria (PNH)]]. ''(Based on APPLY-PNH & APPOINT-PNH)'' |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' LNP-023 |
| + | *'''Brand name:''' Fabhalta | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 20: | Line 22: | ||
[[Category:Factor B inhibitors]] | [[Category:Factor B inhibitors]] | ||
[[Category:Paroxysmal nocturnal hemoglobinuria medications]] | [[Category:Paroxysmal nocturnal hemoglobinuria medications]] | ||
| − | [[Category: | + | |
| + | [[Category:REMS program]] | ||
| + | [[Category:FDA approved in 2023]] | ||
Latest revision as of 01:55, 29 June 2024
General information
Class/mechanism: orally bioavailable, highly potent and highly selective factor B inhibitor. Blocks the alternative pathway of complement upstream of both CD55 and CD59. Iptacopan is used in diseases involving abnormal complement-mediated activity, such as paroxysmal nocturnal hemoglobinuria (PNH).
Route: oral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, UpToDate (courtesy of Lexicomp)
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-12-05: Approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). (Based on APPLY-PNH & APPOINT-PNH)
Also known as
- Code name: LNP-023
- Brand name: Fabhalta